The anti-interleukin agent romilkimab showed significant benefits on skin fibrosis among patients with systemic sclerosis in a phase II trial, researchers reported. At week 24, the least squares mean ...
Nov 14 (Reuters) - Corbus Pharmaceuticals Holdings Inc said its lead drug outperformed a placebo in a mid-stage study involving patients with a form of systemic sclerosis, an incurable autoimmune ...
Epigenetic drugs that have shown promise in cancer trials significantly reduce scarring in the cells of patients with scleroderma, a new study shows. Results reveal that drugs that inhibit BRD4, known ...
(MENAFN- GlobeNewsWire - Nasdaq) Growing Burden of Autoimmune Disorders, Expanding Biologic Pipeline, and Increasing Orphan Drug Support Accelerate Market Expansion. Austin, United States, March 19, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results